Ardelyx has been named an official corporate pharmaceutical marketing partner of the LPGA Tour in a multi-year agreement intended to educate and mobilize patients and support digestive health among women.

The Ladies Professional Golf Association (LPGA) and Ardelyx (Nasdaq: ARDX), a biopharmaceutical company with a vision of creating a healthier tomorrow for patients, today announced a multi-year partnership naming Ardelyx as an official corporate pharmaceutical Marketing Partner of the LPGA Tour. The exclusive partnership unites two organizations dedicated to empowering women to take control of their health.

"This partnership represents a natural alignment between Ardelyxs mission and the LPGAs platform to support the digestive health of women, who account for more than 90 percent of those living with conditions like irritable bowel syndrome with constipation, yet many suffer in silence due to stigma and lack of awareness," said Eric Foster, chief commercial officer of Ardelyx. "By partnering with the LPGA, we will engage with our shared audience, not just as golf fans, but as individuals who deserve open conversations about their health.?At the heart of this first-of-its-kind partnership is the ambition to educate and mobilize patients to be proactive in their health, talk to their doctor and imagine a healthier tomorrow.?The LPGAs commitment to empowering women on and off the course makes them the ideal partner to help us amplify patient voices and break down barriers to care."

Together, Ardelyx and the LPGA will champion a movement that redefines how people talk about irritable bowel syndrome with constipation (IBS-C). IBS-C significantly impacts patients daily lives, affecting mental health, relationships, work productivity and independence. However, societal taboos around digestive health often prevent open dialogue, leaving patients feeling isolated.?As part of the partnership, Ardelyx and the LPGA will educate, encourage and connect patients experiencing symptoms of IBS-C and remind them that they are not alone in their journey. Through original digital and social content distributed across LPGA platforms, the collaboration aims to help patients make informed, confident and proactive decisions about their health. These values resonate with the LPGA's mission to inspire, transform, and advance opportunities for women in golf.

"As we welcome Ardelyx as our official pharmaceutical partner, we look forward to strengthening our existing commitment to supporting healthy lifestyles," said Monica Fee, LPGA Chief Sales and Partnerships Officer. "Together, through Ardelyxs dedication to improving the lives of patients and the LPGAs diverse audience, we will advocate for women to be informed and in control of their health."

As an Official Marketing Partner, Ardelyx will activate across key LPGA moments, creating a powerful platform for impact. The 360-degree approach will include onsite experiences, custom storytelling, premium hospitality, player ambassadors and digital and social engagement to connect with women ready to take the next step in their health journey. Additional details on these partnership activations and initiatives will be announced throughout the 2026 LPGA season.

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon
COMTEX_477976304/2227/2026-04-26T00:30:58